These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24372628)

  • 1. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical modelling issues in the RODIN study.
    Moorehead PC
    Haemophilia; 2014 Jul; 20(4):e351-2. PubMed ID: 24827780
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
    van den Berg HM
    Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making clinical decisions on the basis of RODIN.
    Mannucci PM
    Haemophilia; 2014 Mar; 20(2):e174-5. PubMed ID: 24533956
    [No Abstract]   [Full Text] [Related]  

  • 7. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 8. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.
    Jardim LL; van der Bom J; Brommonschenkel CC; Gouw SC; Rezende SM;
    Br J Haematol; 2019 Jul; 186(1):152-155. PubMed ID: 30556277
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of an inhibitor in a man with mild haemophilia A.
    Evans MS; Eyster ME
    Haemophilia; 2017 Sep; 23(5):e473-e474. PubMed ID: 28750480
    [No Abstract]   [Full Text] [Related]  

  • 13. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 14. A close insight to factor VIII inhibitor in the congenital hemophilia A.
    Tabriznia-Tabrizi S; Gholampour M; Mansouritorghabeh H
    Expert Rev Hematol; 2016 Sep; 9(9):903-13. PubMed ID: 27367203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
    Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
    Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
    [No Abstract]   [Full Text] [Related]  

  • 18. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
    Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
    Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant factor VIII].
    Tusell JM
    Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
    [No Abstract]   [Full Text] [Related]  

  • 20. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.